Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Lower doses tend to have fewer side effects, but long-term outcomes are unknown
13.5% of participants in the semaglutide group discontinued their treatment due to side effects, compared to 27.6% with liraglutide
Semaglutide is degraded by proteolytic enzymes and does not rely on hepatic cytochrome P450 metabolism, whilst topiramate undergoes limited hepatic metabolism and is primarily excreted unchanged in urine
The mechanism enhanced phosphatidylcholine synthesis and improved VLDL export directly targets the hepatic lipid accumulation that defines fatty liver
Patients: 711 adult patients with T2D receiving metformin alone or metformin with an SGLT-2i were randomized to semaglutide tablets 14 mg (n=285), liraglutide 1.8 mg subcutaneous injection (n=284), or placebo (n=142), all once daily
US$ 25.89
US$ 22.74
US$ 21.70
US$ 21.35
US$ 24.76
